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Abstract 
Background: To determine the effects of 40 mg of pravastatin, 2 g of phytosterols, and combination therapy on lipid 
profiles and to compare the reduction of LDL cholesterol between combination therapy and monotherapy.
Methods: Thirty-six HIV-infected patients treated with ARVs who had high LDL cholesterol levels but no current 
usage of any lipid-lowering agents were enrolled into the open-labelled, randomized, cross-over study. All patients 
were assigned randomly into one of four intervention groups: (1) pravastatin 40 mg cross-over to the combination 
of pravastatin 40 mg and phytosterols 2 g (combination group), (2) the combination group cross-over to pravastatin 
40 mg, (3) phytosterols 2 g cross-over to the combination group, and (4) the combination group cross-over to phytos-
terols 2 g. Each active treatment lasted 4 weeks with a wash-out period of 4 weeks.
Results: The baseline mean TC, TG, HDL-c, and LDL-c levels in 36 HIV patients were 248.09 ± 34.73, 172.36 ± 125.44, 
54.92 ± 16.67, and 175.13 ± 29.00 mg/dl, respectively. Pravastatin, phytosterols, and combination therapy reduced 
TC and LDL-c but TG and HDL-c were not significantly different from the baselines. The mean LDL-c reductions in the 
pravastatin, phytosterols, and the combination groups were 28.76 ± 9.32, 9.12 ± 7.84, and 27.08 ± 15.58%, respec-
tively. The LDL-c levels in the pravastatin and combination groups were reduced more than in the phytosterols group 
(p < 0.01). There was no difference in the LDL-c reduction between the combination and pravastatin monotherapy 
groups (−25.61 ± 10.43 vs. −28.12 ± 14.07%, p = 0.555).
Conclusion: Pravastatin had moderate potency on LDL-c lowering in HIV patients but could not bring LDL-c to goal. 
Adding phytosterols to pravastatin for a 4-week duration could not demonstrate any additional lipid-lowering effect
Trial registration: Thai Clinical Trial Registry: TCTR20150126002 date: January 23, 2015
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Background
After the introduction of highly active antiretroviral 
therapy (HAART) together with a proper opportunis-
tic infection prophylaxis regimen, HIV-infected patients 
(HIV patients) have a longer lifespan and better quality 
of life from a major reduction of AIDS-related mortality 
and morbidity. This improved longevity of HIV patients 
led to rising concerns about non-AIDS-related condi-
tions [1], especially cardiovascular disease (CVD) [2]. 
One risk factor contributing to the increase in CVD 
among HIV patients using antiretroviral agents (ARVs) 
is an abnormal lipid profile. From the Data Collection on 
Adverse Events of Anti-HIV Drugs (DAD), the incidence 
of myocardial infarction increased with longer exposure 
to ARVs [3] and the prevalence of elevated total choles-
terol (TC) (TC ≥240  mg/dL), low high-density lipopro-
tein cholesterol (HDL-c) (HDL-c ≤35 mg/dL) or elevated 
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triglycerides (TG) (TG ≥204  mg/dL) also increased [4]. 
Mechanisms of abnormal lipid profile in HAART-treated 
HIV patients included increased de novo hepatic lipo-
genesis, increased secretion of very low-density lipopro-
tein (VLDL) and decreased clearance of VLDL, increased 
synthesis and decreased catabolism of apolipoprotein 
(Apo) B, and increased atherogenic low-density lipo-
protein cholesterol (LDL-c) level including small dense 
LDL-c and oxidized LDL-c [5].
HMG-CoA reductase inhibitors or statins are the 
main agents to reduce the LDL-c level in most patients 
including HIV patients; however, more than 50% of 
HIV patients usually do not reach the LDL-c target 
defined by NCEP/ATP-III [6, 7]. The drug interaction via 
cytochrome P450 3A4 isozyme (CYP3A4) is the major 
concern in the use of HMG-CoA reductase inhibitors 
together with anti-retroviral agents (ARVs). The coad-
ministration of simvastatin or lovastatin with protease 
inhibitors (PIs) is contraindicated [8]. Atorvastatin or 
rosuvastatin may be used in reduced dosages [8]. The 
most recent guideline suggests the use of pravastatin, 
atorvastatin, and fluvastatin to lower cholesterol in HIV 
patients but with the known pharmacokinetics of pravas-
tatin was chosen mainly from its safety profile [8]. This 
unmet LDL-c target may be from the small dosage of 
potent statins used or the weak potency of an allowed 
statin to be used in patients taking HAART. Phytoster-
ols, which are plant sterols/stanols and are classified as 
food, lower cholesterol by competitively binding with the 
Niemann-Pick C1-like 1 (NPC1L1) intestinal sterol trans-
porter and lead to reduced gut cholesterol absorption. 
This mechanism of action is very similar to ezetimibe. 
In clinical experiments, when phytosterols are combined 
with statins there is an increase of LDL-c lowering effi-
cacy of statins [9].Their effects on lipid metabolism have 
been studied and it was concluded that phytosterols are 
safe agents [10]. Thus, phytosterols are recommended as 
an LDL-c lowering agent in diet therapy in many guide-
lines [11–13]. However, there is no study report of their 
efficacy and safety in patients taking HAART.
This research aimed to study the efficacy of lipid-low-
ering treatment and short-term safety of a combination 




The subjects were HIV-infected patients recruited from 
the Infectious Clinic in the Outpatient Department of 
Songklanagarind Hospital from 22 November 2012 to 
27 February 2014. All participants gave written informed 
consent. Inclusion criteria were HIV patients aged 
20 years or older whose LDL-c was 130 mg/dL or higher 
at least 2 times in 3 months apart and the ARV regimen 
was unchanged within the previous 6  months. Exclu-
sion criteria were active opportunistic infection, treat-
ment with any lipid-lowering agents during the 2-month 
period before enrollment, hypersensitivity to any statins, 
and a transaminase enzyme level that was three times 
higher than the upper limit of normal.
Study design
The medical ethics committee of Prince of Songkla 
University, Thailand approved the open-labelled, rand-
omized, cross-over study. All participants were screened 
by coordinating nurses and all who met the criteria were 
randomized into one of four groups by a research coordi-
nator using block randomization with a block size of four. 
Randomization was stratified by ages, sexes, and LDL-c 
levels. Only the investigators were blinded to the treat-
ment allocation.
  • Group 1. Pravastatin 40 mg cross-over to a combina-
tion group
  • Group 2. Combination group cross-over to pravasta-
tin 40 mg
  • Group 3. Phytosterols 2  g cross-over to a combina-
tion group
  • Group 4. Combination group cross-over to phytos-
terols 2 g
The flow of the trial is shown in Figure 1. In summary, 
the duration of the study was 12 weeks and was divided 
into 3 phases: 2 different active treatment phases sepa-
rated by a wash-out phase. The medical history and 
physical examination of the patients taken at baseline 
included age, BMI, underlying diseases, duration of HIV 
infection, CD4 status and current ARVs. The biochemical 
tests at baseline and at the end of each intervention phase 
to determine the efficacy of each intervention included 
TC, TG, HDL-c, and LDL-c. Serum SGOT, SGPT, CPK, 
prothrombin time, and creatinine were collected at base-
line and at the end of each intervention phase to deter-
mine the short-term safety of the interventions. Subject 
compliance was assessed by interviewing and counting 
residual pills and phytosterol products. Subjects who 
took pills or products less than 80% of the requirements 
were determined to be noncompliant. The subjects were 
asked to report any adverse effects at every follow-up 
time. All subjects were instructed to continue their usual 
lifestyle as well as dietary pattern.
Pravastatin and phytosterol product
Pravastatin was taken after dinner once daily and phytos-
terols were taken in the form of a cereal beverage in the 
morning once daily. Tablets of 40  mg of pravastatin for 
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the study were purchased from Daiichi Sankyo, EUROPE 
GmbH. The phytosterol product for the study was Hearti 
Benecol® which contained 2  g of plant stanols per pack 
and was purchased directly from Sahapattanavibool Co., 
LTD., Thailand. A multivitamin preparation was the pla-
cebo for pravastatin with Nestvita® (Nestle Thailand) 
which minimized an excess of calories from Hearti Bene-
col® (Table 1). The nutritional facts of both products were 
provided by the manufacturers.
Biochemical analysis
Venous blood samples were drawn between 8:00 a.m. and 
10:00 a.m. after a 12-h fast. Serum aliquots were stored 
at room temperature and transported to the laboratory 
for testing on the same day. The fasting serum analy-
ses of TC, TG, HDL-c, and LDL-c were measured by an 
enzymatic in vitro assay for direct quantification using a 
MODULAR P800 analyzer (Roche diagnostic, Switzer-
land). The intra- and inter-assay coefficient of variation to 
measure the parameters of total cholesterol, triglyceride, 
HDL-c, and LDL-c was less than 5%.
Outcomes
The primary outcome was to compare the percent reduc-
tion of LDL-c of combination therapy to monotherapy. 
The secondary outcome was to determine changes of TC, 
TG, HDL-c, and LDL-c after the first phase of the pravas-
tatin, phytosterols, and combination groups. The safety 
outcomes were any adverse events including nausea/
vomiting, myalgia, increase in serum creatinine, myositis 
(defined as a CPK level more than five times the upper 
normal limit), and hepatitis (defined as a transaminase 
level more than three times the upper normal limit).
Sample size calculation
The sample size was determined by simulation using a 
parallel group study design. LDL-c levels were assumed 
to have a normal distribution with a mean of 190  mg/
dL and a standard deviation of 30. Three groups were 
created with these baseline parameters. For the after-
treatment values, the data were duplicated to have mean 
LDL-c levels that were 10% lower for the group receiv-
ing phytosterols and 30% lower for the group receiving 
pravastatin.
For the group receiving the combination, the LDL-c 
levels were reduced by 50%, which was more than 
twice the additive effect of each drug alone. With these 
Figure 1 Diagram of cross-over study.
Table 1 Nutritional facts of  phytosterol-enriched cereal 
beverage and standard cereal beverage
Hearti Benecol® Nestvita®
Total calories (kcal/1pack) 110 100
Total fat (g) 4 2
Total protein (g) 2 4
Total carbohydrate (g) 17 17
 Fiber 1 4
 Sugar 3 10
Total plant stanols 2.0 0
Plant stanol ester 1.15
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parameters, a dataset was created and a linear regression 
model was fit to the data and simulated 1,000 times. The 
number of simulations, which resulted in a significant p 
value for the interaction between the drugs and time, was 
recorded and the proportion determined as the power of 
the study. For a sample size of 20 persons per treatment 
arm, the power was calculated to be 88%. For a cross-
over study, the authors assumed that half of the sample 
size would be adequate, that is, 10 patients per treat-
ment arm. With an estimated drop-out rate of 20%, the 
total number of subjects required for a four-arm cross-
over study was 48 patients. An interim analysis was done 
annually to determine the synergistic effect of the combi-
nation therapy on the lipid profile.
Statistical analysis
The baseline characteristics were expressed as 
mean  ±  SD for parametric data, median and range for 
non-parametric data, and numbers and percent for cat-
egorical data. To determine the differences of baseline 
characteristics among the four study groups, one-way 
analysis of variance (ANOVA) was used for parametric 
data, the Kruskal–Wallis Test was used for non-paramet-
ric data, and the Likelihood Ratio test was used for cat-
egorical data.
To determine the primary outcome, paired Student’s t 
test was used to determine the mean difference of base-
line LDL-c between the two intervention phases and 
the percent LDL-c reduction between monotherapy and 
combination therapy. To determine the secondary out-
come, one-way ANOVA with least significant difference 
post hoc test correction was used. P values <0.05 were 
determined as statistically significant. R-3.1.2 for Win-
dows was used for data analysis.
To determine the carryover effect for cross-over study 
design, mixed linear regression model with lm4 package 
in R program was used to test the effect.
Results
Thirty-nine HIV patients were screened and 36 HIV 
patients were enrolled into the study from 22 Novem-
ber 2012 to 27 February 2014. There were 34 subjects 
who completed the first phase and 33 patients who 
completed the second phase. Two subjects were lost 
to follow-up before the end of the first phase and one 
subject was excluded from the analysis due to adverse 
effects. Thirty-three subjects who completed the second 
phase were included into the primary outcome analy-
sis and 34 subjects who completed the first phase were 
included into secondary outcome analysis (Figure  2). 
The baseline characteristics of each treatment group are 
summarized in Table 2. There were no differences in the 
baseline characteristics among the 4 treatment groups. 
The mean age of all patients was 44.68 ±  7.4  years old, 
mean BMI was 22.60  ±  2.83  kg/m2, mean HIV dura-
tion was 7.91 ± 5.4 years, and the mean CD4 status was 
561.47  ±  316.10  cells/cmm. Of the 36 patients, 63.9% 
were male. One subject had diabetes, one subject had 
hypertension, four subjects were using PIs and three 
subjected had unsuppressed HIV viral load. The baseline 
means of the TC, TG, HDL-c, and LDL-c levels in the 
36 HIV patients were 248.09 ±  34.73, 172.36 ±  125.44, 
54.92  ±  16.67, and 175.13  ±  29.00  mg/dl, respec-
tively. The baseline LDL-c levels in Groups 1–4 were 
172.76  ±  43.23, 187.78  ±  26.46, 162.80  ±  11.29, and 
180.68  ±  41.86  mg/dl, respectively. One subject was 
determined as noncompliant.
The changes in the LDL-c levels of the 4 groups are 
shown in Figure 3. After the wash-out period, the LDL-c 
levels returned to similar baseline levels of the first phase 
(data not shown) except in Group 2 in which the sec-
ond baseline was slightly but significantly lower than the 
first baseline. (186.19 ± 26.18 vs. 170.95 ± 32.31 mg/dL, 
p =  0.042). The statistical difference of carryover effect 
was not observed in this study (Additional file 1).
The data from Groups 1 and 2 were used to deter-
mine the difference of LDL-c reduction between the 
pravastatin monotherapy and the combination therapy 
while the data from Groups 3 and 4 were used for phy-
tosterols monotherapy and the combination therapy. A 
comparison of the LDL-c reduction efficacies between 
each monotherapy and combination therapy are shown 
in Figure 4. There were no differences of LDL-c reduc-
tion between the combination therapy and pravasta-
tin monotherapy (25.61  ±  10.43 vs. 28.12  ±  14.07%, 
p  =  0.555). The LDL-c reduction of combination 
therapy was better than phytosterol monotherapy 
(24.12 ± 16.56 vs. 5.11 ± 13.66%, p = 0.005).
The lipid reducing efficacies of pravastatin, phytos-
terols, and combination therapy were determined after 
4  weeks of the first phase intervention and the results 
are shown in Table  3. The decreased mean percentages 
of TC in the pravastatin, phytosterols, and combina-
tion therapy groups were 17.79 ± 5.44, 4.16 ± 7.60, and 
17.70 ± 12.64, respectively, and the decreased mean per-
centages of LDL-c were 28.76 ±  9.32, 9.12 ±  7.84, and 
27.08  ±  15.58, respectively, (pravastatin or the combi-
nation therapy compared to phytosterols, p < 0.01). The 
TG levels remained unchanged in all treatment groups 
although there was a small decrease in the pravastatin 
treatment group. However, the magnitude of change was 
not statistically significant. The changes in the HDL-c 
showed some similarities to that of TG; there was some 
nonsignificant rising of HDL-c in the pravastatin group, 
whereas in the phytosterols or combination group there 
were no substantial changes in the HDL-c levels.
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When the HIV patients were separated according to 
the reduction of LDL-c by pravastatin into good and poor 
response using the mean value of 25.6%, a trend of inter-
action was demonstrated between the addition of phytos-
terols and the responsiveness to pravastatin. Phytosterols 
reduced LDL-c further from a mean of 17.54 ±  6.30 to 
31.88 ± 14.68% (p = 0.052) in the poor response group 
while adding phytosterols to the good response patients 
possibly interfered with the LDL-c reducing efficacy of 
pravastatin (33.64 ± 6.81 to 24.36 ± 13.16% (p = 0.132) 
(Figure 5).
Safety
One subject had an elevated serum transaminase enzyme 
just above 3 times of the upper normal limit after receiv-
ing pravastatin monotherapy. However, this subject 
had active hepatitis B with a twofold elevated transami-
nase enzyme at baseline. His transaminase enzyme level 
declined to his baseline after withdrawal of pravastatin.
Discussion
To our knowledge, this is the first study to determine the 
effects of a combination of pravastatin and phytosterols 
to lower LDL-c in HIV-infected patients taking HAART. 
Many guidelines recommend rosuvastatin, fluvastatin, 
and pravastatin as the statins of choice in HIV-patients. 
These statins do not interfere with ARVs and the rec-
ommended initial dosage of pravastatin is 40 mg/day. In 
the general population, 40 mg of pravastatin showed an 
efficacy in LDL reduction of 29.7% [14]. The efficacy of 
40 mg of pravastatin on LDL reduction in HIV-infected 
patients in placebo-controlled trials was approximately 
20% [15, 16]. Head-to-head studies compared the effi-
cacy of different statins, including 10 mg of rosuvastatin 
and 10  mg of atorvastatin among HIV-infected patients 
who received protease inhibitors. These studies also con-
firmed that the LDL-reduction efficacies of 20  mg and 
40  mg of pravastatin were 17.6 and 19%, respectively 
[17, 18]. During the first phase, the data confirmed the 
Figure 2 CONSORT flow diagram.
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efficacy of 40 mg of pravastatin in those patients taking 
HAART. The LDL-c reduction efficacy of pravastatin was 
approximately 29%, which was similar to the non-HIV 
infected patients from a previous study [14] and seemed 
to be better when compared to studies among HIV-
infected patients. This may be because the proportion of 
PI used in this study was very low compared to previous 
studies [15, 16, 18].
Table 2 Baseline characteristics of subjects
Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, phytosterols then combination; Group 4, combination then phytosterols.
a Kruskal–Wallis Test.
b One-way ANOVA.
c Likelihood Ratio test.
d Suppressed HIV viral load defined by HIV viral load <50 copies/ml.
Mean ± SD or median (min,max) or number (%) p value
Group 1 (n = 11) Group 2 (n = 9) Group 3 (n = 8) Group 4 (n = 8)
Age, year 47.94 ± 7.73 45.33 ± 8.66 41.12 ± 7.72 43.00 ± 7.41 0.23b
BMI, kg/m2 22.48 ± 2.40 22.68 ± 3.64 23.63 ± 3.07 21.61 ± 2.45 0.59b
Male, no. 8 (72.7) 7 (77.8) 4 (50) 4 (50) 0.48c
Diabetes, no. 0 1 (11.1) 0 0 0.41c
Hypertension, no 1 (9.1) 1 (11.1) 0 0 0.48c
PIs, no. 2 (18.2) 1 (11.1) 0 1 (12.5) 0.50c
NNRTI, no. 9 (81.8) 8 (88.9) 8 (100) 7 (87.5)
Suppressed HIV viral load, nod 9 (81.8) 8 (88.9) 8 (100) 8 (100) 0.27c
HIV duration, years 5.61 ± 5.21 11.11 ± 3.79 6.61 ± 4.51 8.78 ± 7.11 0.13b
CD4, cell/cmm 514.27 ± 331.71 678.22 ± 438.85 612.62 ± 270.87 443.88 ± 152.96 0.45b
Creatinine, mg/dL 0.90 ± 0.19 0.95 ± 0.28 0.94 ± 0.35 0.73 ± 0.13 0.29b
SGPT, mg/dL 35.81 ± 24.46 35.66 ± 15.02 30.13 ± 12.77 27.50 ± 8.18 0.67b
HDL-c, mg/dL 52.07 ± 13.23 53.04 ± 12.08 57.73 ± 20.93 58.13 ± 23.15 0.83b
LDL-c, mg/dL 175.75 ± 36.90 186.99 ± 24.60 163.01 ± 9.65 173.04 ± 35.24 0.43b
TC, mg/dL 222.0 (197,301) 245.0 (227,353) 242.5 (191,285) 242.0 (202,297) 0.48a
TG, mg/dL 134.0 (64,390) 176.00 (53,620) 106.50 (58,499) 109.0 (52,367) 0.54a
CPK, mg/dL 131.0 (46,876) 150.0 (87,234) 133.5 (60,289) 123.0 (79,532) 0.96a
Figure 3 Baseline of serum LDL-c of phase 1 and phase 2 of each group. Baseline 1, baseline LDL-c level before the start of active treatments in 
phase 1; baseline 2 LDL-c level after the washout period; Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, 
phytosterols then combination; Group 4, combination then phytosterols.
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The LDL-c reduction efficacy of phytosterols in this study 
was 9.12% which was similar to a previous study in the Thai 
population which showed a 8.9% LDL-c reduction [19]. 
The effect of phytosterols on LDL-c reduction was modest 
(8–14%) in accordance with previous studies [20–22]. One 
meta-analysis reported that the efficacy of 2 g/day of plant 
stanols or sterols was a reduction in the LDL-c levels by 
10% [23]. The effect of phytosterols on triglyceride levels 
Figure 4 Comparison of LDL-c reduction between combination therapy and monotherapy. Pravastatin pravastatin, monotherapy in Groups 1 and 
2; combination 1, combination therapy in Groups 1 and 2; phytosterols, phytosterols monotherapy in Groups 3 and 4; combination 2 combination 
therapy in Groups 3 and 4.
Table 3 Percent change of lipid parameters in each treatment group at the end of the first phase
* Significantly different between either pravastatin or combination compared to phytosterols group (p = 0.002).
Lipid parameters Pravastatin (n = 11) Phytosterols (n = 8) Combination (n = 15) p value
Mean SD Mean SD Mean SD
TC −17.79 5.44 −4.16 7.60 −17.70 12.64 0.006*
TG −16.33 29.82 −4.08 23.98 −0.52 42.09 0.516
HDL-c 5.27 8.47 −0.07 14.07 −2.31 12.97 0.290
LDL-c −28.76 9.32 −9.12 7.84 −27.08 15.68 0.003*
Figure 5 Effects of phytosterols on patients who had good response and poor response to pravastatin. Pravastatin, pravastatin monotherapy in 
Groups 1 and 2; combination combination therapy in Groups 1 and 2; poor response, subgroup pravastatin with an LDL-c reduction less than 25.6%; 
good response, subgroup pravastatin with an LDL-c reduction more than 25.6%.
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and HDL-c was very little, which was similar to one meta-
analysis that reported no effect of phytosterols on triglyc-
eride and HDL-c levels [9]. The ESC/EAS guideline also 
reported that 2  g daily of phytosterols reduced total cho-
lesterol and LDL-c by 7–10% with little or no effect on TG 
and HDL-c when it was consumed with the main meal [24]. 
Thus, the effectiveness of a phytosterol product on the lipid 
profiles in this study was similar to previous reports.
The LDL-c reduction efficacy of the combination ther-
apy was 28% which was similar to pravastatin monother-
apy. With this cross-over design, there was no difference 
in percent changes of LDL-c levels between the combi-
nation therapy and pravastatin alone. It was surprising 
that the effect of phytosterols in lowering LDL-c was not 
observed when the phytosterol product was combined 
with pravastatin. The possibilities could be from the short 
duration of statin treatment, low rates of cholesterol 
absorption in the patients, or compliance issues of these 
vulnerable subjects.
The effect of duration of statin treatment might play a 
major role on the effect of phytosterols. The mechanism of 
action of HMG-coA reductase inhibitor includes the inhi-
bition of hepatic LDL-c synthesis, which leads to upregu-
lation of LDL-R expression and leads to a compensatory 
increase of cholesterol absorption from the intestine [25, 
26]. The action of phytosterols should be seen clearly only if 
the intestinal cholesterol absorption is substantial. A meta-
analysis on the effect of adding plant sterols or plant stanols 
to statins on LDL-c showed that add-on phytosterols to sta-
tin therapy was better than statin alone [9]. However, most 
of the included trials studied patients who took a steady 
dosage of statin for at least 8 weeks before adding phytos-
terols. However, a study by Gylling et al. [22] also enrolled 
naïve patients and showed a benefit of combining phy-
tosterols with statin therapy. The difference between this 
study and the Gylling study was the duration of the active 
phase. The patients in this study were on active treatment 
for only 4 weeks each. In the Gylling study, the duration of 
each treatment phase was 7 weeks. However, Simons and 
colleagues demonstrated the additive effect of approxi-
mately 6% of add-on phytosterols to cerivastatin sodium 
when the subjects started simultaneously for a duration of 
4 weeks [20]. The difference in this study from the Simons 
study was the statin used. Cerivastatin is a potent statin and 
the effect of NPCL1 inhibition on LDL-c reduction is more 
pronounced [25]. An additional LDL-c lowering effect of 
phytosterols on statin therapy was not demonstrated in 
this study possibly because the dietary patterns and other 
changes during the study were not monitored.
From the subgroup analysis of this study, the poorer 
effect of phytosterols on good responders indicated 
another hypothesis concerning the differentiation of 
synthesis and absorption of cholesterol. Phytosterols 
would have an additive effect on LDL reduction only in 
patients with low rates of cholesterol synthesis and high 
rates of cholesterol absorption. The poor responders of 
the pravastatin subgroup would be the ones with low 
rates of cholesterol synthesis and high rates of cholesterol 
absorption and in this group of patients, the phytosterols 
should exhibit their maximal effect.
This study reported good compliance of most subjects 
and apparent compliance in counting the residual pills 
and products. However, there was no objective proto-
col to assure real compliance as these patients also had 
to take a large number of drugs. However, from the 
accepted LDL-c reduction between the pre- and post-
interventions of each phase, compliance of the subjects 
was not a major problem.
The limitations of this study were the small sample 
size and the unblinded fashion of the study design of 
the patients. The small sample size was not unexpected 
among this kind of vulnerable patients. They used mul-
tiple medications and were not willing to participate in a 
prevention trial which could not demonstrate any benefi-
cial effect. To correct this limitation, a multicenter study 
could be the solution. Another limitation was the open-
labelled study design. The patients knew the products 
and medicines, which possibly affected their behavior 
and diet. For example, in the group that had the non-phy-
tosterol-enriched product possibly tried to control their 
behavior while the other group that had the phytosterol-
enriched product possibly had poorer food choices. Since 
this present study did not design for dietary control and 
monitoring, this confounder could not be demonstrated.
One of the strengths of this study is that it is the first 
study that used phytosterols to reduce LDL-c in HIV 
patients (Additional file  2). The other strength was the 
emphasis on the recommended diet by standard guide-
lines in which 2  g of phytosterols could reduce LDL-c 
level in HIV patients.
In this study, pravastatin was safe for patients taking 
HAART. Only one patient had asymptomatic elevated 
transaminase enzyme but that patient also had chronic 
active hepatitis virus B.
Conclusion
Pravastatin had moderate potency on lowering the LDL-c 
levels in HIV patients but could not bring LDL-c to goal. 
Adding phytosterols to pravastatin for the 4-week duration 
could not demonstrate any additive lipid-lowering effect.
Additional files
Additional file 1. Testing carryover effect on LDL-c outcome. 
Additional file 2. CONSORT 2010 checklist of information to include 
when reporting a randomised trial.
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